OncoMatch/Clinical Trials/NCT06234605
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Is NCT06234605 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including HC-7366 and Belzutifan for renal cell carcinoma.
Treatment: HC-7366 · Belzutifan — This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- University of California San Diego Moores Cancer Center · La Jolla, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of Colorado Anschutz Medical Campus · Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP · Lone Tree, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify